Materials and Methods
Cell lines and reagents. HeLa [American Type Culture Collection (ATCC CCL-2), TZM-bl cells [NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH, from Dr. John C. Kappes and Dr. Xiaoyun Wu; Cat#8129; (1)], and Human embryonic kidney 293T cells (ATCC CRL-3216) were maintained as previously described (2, 3) . CEM-SS cells (NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH; gift from Dr. Peter L. Nara; Cat#776) and THP-1 cells (ATCC TIB-202) were maintained in Roswell Park Memorial Institute (RPMI) 1640 medium (CellGro, Manassas, VA) supplemented with 10% fetal calf serum (HyClone, Logan, UT) and 1% penicillin-streptomycin (penicillin 50 U/ml and streptomycin 50 µg/ml; Lonza, Walkersville, MD). THP-1 cells were differentiated with phorbol myristyl acetate treatment (Sigma-Aldrich, St. Louis, MO; 100 ng/ml) for 48 hours to generate THP-1-derived macrophages.
To generate the HeLa-Bgl cell line, pLVX-TRE3G-Bgl-mCherry, a lentiviral vector that expresses truncated bacterial protein BglG that is fused to mCherry at the C-terminus and contains a nuclear localization signal (Bgl-mCherry) from a doxycytidine-inducible promoter was first created. Bgl-mCherry, which specifically binds to Bgl RNA stem loops (4) , was cloned into lentiviral vector pLVX-TRE3G (Clontech, Mountainview, CA) to generate pLVX-TRE3G-Bgl-mCherry. HeLa cells were transduced with pLVX-TRE3G-Bgl-mCherry and Tet-On 3G, which expresses the transactivator protein, and the transduced cells were maintained in complete media containing puromycin (1 µg/ml; Thermo Fisher Scientific) and G418 Sulfate (200 µg/ml; Sigma-Aldrich); a single cell clone expressing a low level of Bgl-mCherry was obtained by limiting dilution to generate the HeLa-Bgl cell line.
To generate the HeLa-Bgl:Tat-Rev cell line, a murine leukemia virus (MLV)-based vector that expressed HIV-1 Tat and Rev was first created by transferring a cassette that expresses a hygromycin b phosphotransferase gene (5) from an internal ribosomal entry site (IRES) from WH450, a spleen necrosis virus vector, into MLV-based vector pAR2 (6) . Next, a cassette containing codon-optimized HIV-1 Tat and Rev separated by an in-frame self-cleaving peptide from porcine teschovirus 2A [P2A; (7) ] was inserted upstream of IRES-Hygro to generate MLV-Tat-P2A-Rev-IRES-Hygro. Infectious virions were produced by co-transfection of MLV-Tat-P2A-Rev-IRES-Hygro along with MLV gag-pol expression plasmid pLGPS (8) To generate the HeLa:mRuby-CPSF6 cell line, HeLa cells constitutively expressing an shRNA targeting CPSF6 were first generated by transduction with a lentiviral vector (pLKO.1 hygro; gift from Bob Weinberg; Addgene plasmid #24150), which was modified to express the shRNA targeting CPSF6 (5'-AGACCGTCATGACGATTATTA-3'). A control cell line that expresses a non-targeting control shRNA from the human U6 promoter was also constructed.
The transduced cells were selected for resistance to hygromycin (200 µg/ml). Next, pLVX-EF1-mRuby-CPSF6-P2A-Puro, a lentiviral bicistronic vector that expresses mRuby-CPSF6 that is resistant to the CPSF6 shRNA under the control of the human EF1 promoter was created.
Briefly, the IRES-Puro cassette in the lentiviral vector pLVX-IRES-Puro (Cat# 632183, Clontech) was replaced with mRuby, which was amplified by PCR from mRuby-LaminB1-10 (Addgene plasmid #55869), and the CMV promoter was replaced with the human EF1 promoter. Next, an shRNA-resistant CPSF6 (GenBank NM_007007.2; synonymous mutations in the nucleotide sequence targeted by CPSF6 shRNA were introduced) and an in-frame P2A fused to Puro were synthesized as multiple gBlocks (Integrated DNA Technologies, Inc., Coralville, Iowa). These fragments were assembled downstream of mRuby by Gibson Assembly (New England Biolabs, Inc., Ipswich, MA), generating the lentiviral vector pLVX-EF1-mRuby-CPSF6-P2A-Puro. The HeLa cells stably expressing the CPSF6 shRNA were transduced with the lentiviral vector pLVX-EF1-mRuby-CPSF6-P2A-Puro and selected for puromycin resistance (1 µg/ml). The mRuby-CPSF6 fusion protein was expressed in HeLa cells stably expressing CPSF6 shRNA to reduce the amount of endogenous unlabeled CPSF6 and increase the mRuby-CPSF6 labeling efficiency.
To validate the cell lines, endogenous CPSF6 and mRuby-CPSF6 were detected by SDS-PAGE and western blot analysis using an anti-CPSF6 antibody (Sigma-Aldrich; Cat#HPA039973) followed by goat anti-rabbit antibody (IRDye-800CW; LI-COR, Lincoln, NE); HSP90 was used as a loading control and detected using an anti-HSP90 antibody (Santa Cruz Biotechnology, Inc., Dallas, TX; Cat#sc-69703) followed by goat anti-mouse antibody (IRDye-680RD; LI-COR).
Western blots were imaged and quantitated using the Odyssey infrared imaging system (LI-COR).
To generate the CEM-SS-mRuby-LaminB cell line, CEM-SS cells were transduced with the lentiviral vector pLVX-CMV-mRuby-LaminB-P2A-Puro, a bicistronic lentiviral vector that expresses a mRuby-LaminB fusion protein and Puro under the control of the CMV promoter.
Briefly, the mRuby-CPSF6 cassette in pLVX-EF1-mRuby-CPSF6-P2A-Puro was replaced with mRuby-LaminB, which was amplified by PCR from mRuby-LaminB1-10 (Addgene plasmid #55869) and the EF1 promoter was replaced with the CMV promoter. Transduced cells were selected for resistance to puromycin (1 µg/ml). All cells were maintained in humidified 37º C incubators with 5% CO2. Nevirapine (NVP) and raltegravir (RAL) were obtained through the NIH AIDS Reagent Program and were used at final concentrations of 5 μM and 10 μM, respectively. PF-3450074 (PF74; Sigma) was used at a final concentration of 10 μM.
Lentiviral vectors, protein expression vectors, and virus production.
The HIV-1 based vector pHGFP-BglSL was generated by inserting a cassette containing 18 RNA stem loops [BglSL; (4) ], which are specifically recognized by the bacterial Bgl protein 21 , into pHGFP. The RNA stem loops were separated by short (~10 nucleotide) randomized linkers and were inserted into the Vpr-Vif region of the HIV-1 based vector pHGFP. pHGFP is an HIV-1 vector derived from pHL (10) that contains a gfp reporter gene in place of nef and does not express env. The resulting HIV-1 vector expresses a gfp reporter gene and an RNA that contains 18 BglSL, but does not express Vif, Vpr, and Env. To generate the HIV-1 based vector, pHGFP-GFPCA-BglSL, a Y132I mutation in the protease cleavage site between GFP and CA, which prevents cleavage (11) was introduced into HIV Gag-iGFP [NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: gift from Dr. Benjamin Chen; Cat#12457; (12)] by site-directed mutagenesis. A cassette containing MA-GFP-CA (containing the Y132I mutation) was inserted in place of MA-CA in pHGFP-BglSL, generating a HIV-1 vector that is similar to pHGFP-BglSL, except that a GFP-CA fusion protein is generated after proteolytic processing. CA mutants N74D and A77V were generated by site-directed mutagenesis of pHGFP and cassettes containing CA with the mutations were inserted into pHGFP-GFPCA-BglSL and pHGFP-BglSL, generating pHGFP(N74D)-GFPCA-BglSL, pHGFP(N74D)-BglSL, pHGFP(A77V)-GFPCA-BglSL, and pHGFP(A77V)-BglSL, respectively. Infectious virions that were labeled with GFP-CA were prepared by co-transfection of 293T cells with pHGFP-GFPCA-BglSL and pHGFP-BglSL (or similar vectors containing CA mutation), which expresses wild-type gag-pol, at a 1:15 plasmid ratio, and pHCMV-G (13) , which expresses the G glycoprotein of vesicular stomatitis virus (VSV-G). To generate infectious virions that are labeled with GFP-CA, but do not contain BglSL and express Vif and Vpr, a cassette containing MA-GFP-CA (containing the Y132I mutation) was inserted in place of MA-CA in pHGFP, generating a vector (pHGFP-GFPCA) that expresses a GFP-CA fusion protein after proteolytic processing that also expresses Vif and Vpr. Infectious virions that were labeled with GFP-CA and produced in the presence of Vif and Vpr were prepared by co-transfection of 293T cells with pHGFP-GFPCA and pHGFP at a 1:10 plasmid ratio, and pHCMV-G. Infectious virions containing only wild-type gag-pol were produced by cotransfection of 293T cells with pHGFP and pHCMV-G.
A plasmid expressing APOBEC3F (A3F) fused to red-red vine tomato (RRvT) fluorescent protein was generated by replacing YFP in A3F-YFP (3) with RRvT, which was amplified by PCR from pBad-HisB-RRvT [addgene plasmid #87364; (14) ]. To generate infectious virions that were labeled with GFP-CA and A3F-RRvT, a plasmid expressing an A3F-RRvT (1.25 µg) was cotransfected with pHGFP-GFPCA-BglSL, pHGFP-BglSL, and pHCMV-G. To generate singlelabeled infectious virions, plasmids expressing either A3F-YFP, A3F-mNeonGreen (mNG; mNeonGreen was amplified by PCR from pmNeonGreen-N1 (Allele Biotechnology, San Diego, CA) and used to replace YFP in A3F-YFP), Vpr-Integrase-YFP (2) , or Vpr-Integrasesuperfolder(sf)GFP [kindly provided by Dr. Greg Melikyan; (15) ] were co-transfected with pHGFP-BglSL or pHGFPΔVifΔVpr, a pHGFP-derived vector in which the vif and vpr genes were deleted, and pHCMV-G.
To generate cell lines, the lentiviral vectors used to create the cell lines (e.g. pLVX-TRE3G-Bgl-mCherry) were co-transfected with pC-Help (16) , which is an HIV-1 helper construct that expresses gag-pol but lacks several cis-acting elements needed for viral replication, and pHCMV-G. Supernatants from transfected 293T cells were filtered and the HIV-1 particles were concentrated by ultracentrifugation (100,000 × g) for 1.5 hrs at 4 ºC through a 20% sucrose cushion (wt/vol) in 1X phosphate buffered saline (PBS).
Virus infection.
HeLa-based cell lines were seeded in ibiTreated μ-slides (30,000 cells/well; Ibidi, Gräfelfing, Germany) one day prior to infection. The CEM-SS:mRuby-LaminB cell line was seeded into μ-slides (100,000 cells/well) that were pretreated with poly-L-lysine (Sigma-Aldrich; Cat#P8920). THP-1 cells were seeded into μ-slides (50,000 cells/well) and treated with PMA (100 ng/ml) for 48-h prior to spinoculation. Cells were infected with viruses via spinoculation at 16ºC (17) , which permitted virion binding to cell membranes but prevented virion endocytosis. identified manually from z-stacks acquired between 6 and 10 hpi; GFP-CA intensities for these complexes were determined as described above. Of the 116 HIV-1 TS observed (59 in HeLa-Bgl cells and 57 in HeLa-Bgl:Tat-Rev cells), 81 TS were the only TS detected in the cells. When cells had >1 TS, only the timing of the 1 st detectable TS was considered. To visualize the nuclear import of GFP-CA or A3F-mNG particles, similar time-lapse images of the infected cells were acquired as described above, except the movies were started ~10 min after infection.
Distances between the GFP-CA-labeled viral complexes and associated HIV-1 TS were determined using a custom written MATLAB program. Briefly, the image of the nucleus in the last frame GFP-CA signal was detected prior to disappearance and the image of the nucleus in the first frame in which the associated HIV-1 TS was detected were aligned to account for cell movement in between GFP-CA loss and detection of HIV-1 TS. Next, the 3D positions of the GFP-CA particle and HIV-1 TS were determined using 3D gaussian fitting, which were then used to calculate distances. A similar method was used to determine the distance HIV-1 TS moved in ~1.5 hrs.
The distance between the HIV-1 TS and the nucleus boundary was determined using a custom-written MATLAB program. Bgl-mCherry contains a nuclear localization signal; thus, most of the Bgl-mCherry localized inside the nucleus and very low amounts of Bgl-mCherry localized with the NE. We identified nuclear pore complexes (NPCs) in HeLa cells expressing Bgl-mCherry by immunostaining with anti-NPC antibody Mab414 (Abcam, Cambridge, UK; Cat#ab24609) followed by AlexaFluor488-labeled secondary antibody (Thermo Fisher Scientific, Waltham, MA;
Cat#A-11001) and compared the Bgl-mCherry signals localized to the NPCs and inside the nucleus (Fig. S3E-F) . As expected, the Bgl-mCherry signals inside the nucleus were significantly higher than at the NPCs (414 and 145, respectively; Fig. S3F ), indicating that the reduction in the Bgl-mCherry signal can be used to visualize the nucleus boundary. The position of the HIV-1 TS at the time of detection was determined using 3D gaussian fitting. Next, the nearest edge of the Bgl-mCherry signal to the HIV-1 TS was determined and then the 3D distance between the nucleus boundary and the HIV-1 TS was determined.
Fixed-cell imaging and image analysis.
A custom-written MATLAB program was used to determine the colocalization of A3F-RRvT and GFP-CA signals inside the nuclei of infected cells.
First, the A3F-RRvT signals were detected using Localize (19) . Colocalization of the fluorescently-labeled virus particles with a mask of the nucleus interior (based on immunofluorescence staining using an anti-Lamin A/C antibody [Sigma-Aldrich; Cat#L1293 or Thermo Fisher Scientific; Cat#MA3-1000] followed by detection using a AlexaFluor405-labeled secondary antibody [Thermo Fisher Scientific, Cat#A-31553 or Cat#A-31556) was determined using a custom-written MATLAB program as previously described (2) . Next, to determine background signals in the GFP channel, the intensity values in the GFP channel at random positions inside >50 nuclei were determined; the threshold was determined as the mean + 2 SD of the random intensities. The intensity values of the GFP channel at the position of each nuclear A3F-RRvT particle or at random positions in the nuclei were determined; A3F-RRvT particles colocalizing with GFP signals that were above the threshold intensity value were considered positive for GFP-CA. For some experiments, a mask of the NE was also created using the Lamin A/C signal. The percentage of GFP-CA, Integrase-YFP, or A3F-YFP particles that colocalized with the NE mask and the percentage of particles that colocalized with the nucleus mask were determined. To determine the percentage of GFP-CA-or Integrase-sfGFP-labeled viral complexes that were mRuby-CPSF6 + and the intensities of those complexes, the GFP-CA-or Integrase-sfGFP-labeled nuclear complexes in HeLa:mRuby-CPSF6 cells were identified manually from z-stacks acquired 6 hpi. Pixel intensities at the locations of the GFP-CA or Integrase-sfGFP particle signals were determined after subtracting the local background. Nuclear background intensities were determined by selecting 85 random positions from the nuclei of 5 cells and extracting pixel intensities in the mRuby channel; the threshold intensity was determined as the mean + 1 SD of the random intensities in the mRuby channel. GFP-CA or Integrase-sfGFP particles co-localizing with mRuby signals that were above the threshold value were considered positive for mRuby-CPSF6.
Single Virion Analysis (SVA). Fluorescently-labeled virus particles were centrifuged onto ibiTreated μ-slides (1,200 x g for 1 hr). CA was detected using an anti-CA antibody (AG3.0; NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: gift from Dr. Jonathan Allan; Cat#4121) followed by a Cy5-labeled secondary antibody (Thermo Fisher Scientific, Cat#A-10524), and then imaged by spinning disk confocal microscopy. The diffraction-limited spots were detected, and their positions were determined in each image using Localize. The positions of the spots were used to determine colocalization; spots were considered colocalized if the centers of the spots were within 3 pixels.
In vitro analysis of intact virions and viral cores. GFP-CA-labeled virus particles were
centrifuged onto ibiTreated μ-slides (1,200 × g for 1 hr). Intact virions bound to the slides were lysed by saponin treatment in vitro to remove viral membranes and free CA that was not incorporated into viral cores; an equal volume of PBS containing 2X saponin detergent (0.1% final concentration) was added to the wells containing virus particles between the 2 nd and 3 rd time points. Time-lapse images of the virus particles were acquired every 10 seconds for 5 minutes.
A custom-written MATLAB program was used to identify GFP-CA particles and determine their signal intensities. Virus particles that lost ≥33% of the initial GFP-CA signal were considered to lose the viral membrane (typically 90% of particles) and were used for further analysis. Next, the virus particles were separated into three categories; first, some particles (4%) lost all GFP-CA signal at the time of saponin treatment; second, some particles (44%) lost the GFP-CA signal in two discrete steps, losing free GFP-CA that was not incorporated into viral cores at the time of saponin treatment and subsequently losing viral core-associated GFP-CA signal during the 5-min observation time (i.e. uncoated); third, some particles (52%) lost free GFP-CA that was not (Fig. 3C ).
Transmission Electron Microscope (TEM) analysis of virus pellets.
Virus pellets were obtained by ultracentrifugation as described above, washed once in PBS, processed for thinsectioned EM analysis as previously described (20, 21) . Briefly, virus pellets were fixed in 2%
(v/v) glutaraldehyde (Tousimis, Rockville, MD) in 0.1 M sodium cacodylate (pH 7.4; Electron Microscopy Sciences [EMS], Fort Washington, PA), followed by Osmium post fixation (1% Osmium tetroxide v/v in same buffer for 1 hr). The pellets were dehydrated in a series of ethanol solutions (e.g., 35%, 50%, 70%, 95%, 100%) and 100% propylene oxide. An infiltration was made in 1:1 mixture of propylene oxide and epoxy resin (EMS) overnight, and the pellets were embedded in pure resin. The resin was cured for 48 hrs in 55ºC and thin sections (60 to 70 nm) were made with an ultra-microtome equipped with a diamond knife and mounted on naked copper grid. The thin sections were stained in uranyl acetate (EMS) and lead citrate (Leica, Bannockburn, IL), stabilized by carbon evaporation. The sections were examined and images were captured by digital camera in Hitachi 7650 TEM (Hitachi, Tokyo, Japan) operated at 75kv (21) . Virions exhibiting the mature and immature phenotype were scored manually.
Fractionation of viral cores using sucrose gradients. The fractionation of viral cores using sucrose gradients was performed as previously described, with slight modifications (22) . 
